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This comment should start with the 
acknowledgement that we are firm advocates 
of the value of radiotherapy (RT) after radical 
prostatectomy (RP) in many patients with 
prostate cancer. However, we are concerned 
that a published and recently presented study 
(European Organization for Research and 





 [1,2], of adjuvant RT vs observation 
for patients with potentially higher risk 
prostate cancer after RP, used endpoints to 
show a benefit that were not appropriate for 
an adjuvant treatment, and thus might give 
an impression of value that is not clinically 
meaningful.
PSA is a widely used biomarker for the 
diagnosis, risk prediction (prognosis) and 
monitoring of prostate disease activity. The 
attractiveness of PSA as ‘a surrogate marker’ 
in different stages of prostate cancer is 
obvious, as it can be substituted for the 
endpoint of interest in future therapeutic 
trials, thus obtaining the same conclusions 
about treatment comparisons while 
eliminating the need for longer follow-up for 
the definitive endpoint.
In clinical medicine a true endpoint for clinical 
benefit is defined as a characteristic or 
variable that reflects how a patient feels or 
functions, or how long a patient survives. This 
implies that the surrogate endpoint must be 
correlated with the clinical outcome, and that 
the surrogate endpoint must fully capture the 
net effect of treatment on the clinical 
outcome. Trials using PSA-based endpoints to 
‘show clinical benefit’ must have adequate 
power to show that overall survival is no 
worse. In addition, systematic assessment of 
long-term morbidities must also be a factor, 
particularly in the setting of prostate cancer 
where the natural history is long, hence the 
potential for an adverse effect on quality of 
life. It is conceivable that despite an apparent 
benefit in some patients, others might have 
worse survival, as in the case of patients 
undergoing watchful waiting who were 
randomized to a high-dose bicalutamide 
group in the Early Prostate Cancer Program, 
where patient survival appeared to be reduced 
in patients treated with bicalutamide for 
localized disease [3]. Another example is 
the increasing high-density lipoprotein 
cholesterol levels (surrogate endpoint) in 
patients using the novel cholesteryl-ester 
transfer-protein inhibitor torcetrapib, 
which was associated with an increase in 
mortality [4].
Another important consideration is the timing 
of an intervention. An example in another 
disease, immediately recognised by urologists 
and radiation oncologists, is the timing of 
adjuvant chemotherapy for pathological 
stage II testis cancer, which was shown 
by a comparison of adjuvant chemotherapy 
vs chemotherapy at relapse [5]. That study 
found that there was unequivocal evidence 
of a favourable effect of treatment 
(chemotherapy), but the research question 
was about the timing, side-effects and degree 
of treatment to those who were cured by 
surgery alone. As it turned out, adjuvant 
chemotherapy and chemotherapy at relapse 
give similar survival rates, and so the decision 
on when to treat depends on the side-effects 
from the chemotherapy, particularly in those 
who might not need it, and the toxicity and 
reliability of the patient to actually obtain the 
salvage treatment if needed. An endpoint in 
these studies could not have been the delay in 
relapse after surgery. Any therapy that has 
some effect on the disease and could be used 
in an adjuvant setting might delay relapse, 
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but such a finding does not necessarily 
translate into an overall clinical or survival 
benefit compared to treatment later at the 
time of relapse, and must be carefully 
weighed against the disadvantage of treating 
several patients who were ‘cured’ by surgery 
alone.
There is indisputable evidence that some 
fraction of patients will have a durable PSA 
response after salvage RT for an increasing 
PSA level, and thus salvage RT affects the 
disease to some degree [6,7]. A delay in PSA 
relapse (biochemical disease-free survival) 
with adjuvant RT would be entirely 
anticipated unless the treatment was 
worthless, which few think is the case. 
Unfortunately, EORTC trial 22911 had as its 
primary endpoint the prolongation of 
biochemical progression-free survival (or 
delay in PSA relapse) and was powered to 
detect a 7.5% increase in biochemical 
progression-free survival [1,2]. The control 
arm was not early salvage RT at the time of 
PSA relapse. Indeed, most of the clinical 
failures were locoregional and half the 
patients in the control arm did not receive RT 
at any time; of the half who did receive 
salvage RT, many, if not most, received it for a 
clinically evident local recurrence, i.e. certainly 
not early salvage and after the patient had 
already reached an endpoint for failure in the 
study design. Not surprisingly, the study 
showed a benefit for adjuvant RT in delaying 
biochemical or clinical relapse, but no 
improvement in overall survival. In a similar 
South West Oncology Group (SWOG) study 
started in the late 1980s before the 
widespread use of PSA for monitoring after 
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surgery, a design of this type was 
understandable [8]. However, the EORTC study 
was undertaken in 1992 when the PSA test 
was better integrated into patient care.
In 2007, the EORTC 22991 study provided 
interesting data but does not reflect current 
realities and should not be viewed as 
establishing adjuvant RT as optimal care for 
current patients with potential high-risk 
features. Substantial stage migration is 
evident in the last 15 years, such that a 
greater fraction of patients are cured with 
surgery alone, even with adverse features 
such as extracapsular extension or seminal 
vesical invasion [9]. RT has developed such 
that higher doses are given to patients with 
prostate cancer, but with greater precision, so 
the outcomes might be better and patients 
will have fewer complications and a higher 
quality of life. The required study, as planned 
by the UK Medical Research Council, will 
examine adjuvant RT vs early salvage RT for 
endpoints of survival and avoidance of the 
use of hormonal therapy.
A delay in biochemical progression is one 
element in the requirement for adjuvant 
therapy to be beneficial, but it is not 
sufficient alone. If the same survival endpoint 
can be obtained with delayed treatment 
administered only to those who need it, the 
delayed treatment probably has an advantage. 
The absence of level-I data, i.e. a prospective, 
randomized controlled trial that examines the 
current practice of either adjuvant or early 
salvage RT, does not imply that we should 
extrapolate the results of one study, that was 
admittedly carried out well, but unfortunately 
had an insufficient primary endpoint and an 
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Bicalutamide 150 MG in addition to 
standard care in patients with localized or 
locally advanced prostate cancer. results 
from the second analysis of the early 
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 Immediate adjuvant chemotherapy 
versus observation with treatment at 
relapse in pathologic stage II testicular 
cancer. 
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Contemporary survival results and the 
role of radiation therapy in patients with 
node negative seminal vesicle invasion 
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PSA screening for prostate cancer has 
been controversial since its introduction 
almost 20 years ago. Despite conflicting 
recommendations from professional 
societies, PSA has been widely adopted as a 
screening tool in the USA [1]. As a result, 
the incidence of prostate cancer has almost 
doubled; the lifetime risk of being 
diagnosed with prostate cancer in the USA 
is now 18% (SEER report, 1973–1995, 
available at http://seer.cancer.gov/csr/1975-
2004); 90% of these men are currently 
diagnosed with early-stage disease, 
reflecting a significant stage migration [2] 
(http://seer.cancer.gov/csr/1975-2004). 
Proponents of screening have pointed to 
declining prostate cancer mortality rates 
over this period as evidence of the efficacy 
of screening [3]. However, this trend has 
also been observed in regions where PSA 
screening is less prevalent, and others have 
cited improvements in therapy and earlier 
use of androgen-deprivation therapy as the 
cause of this decline [3–5]. The mortality 
data from two large trials evaluating PSA 
screening is expected within the next 
several years and, it is hoped, will resolve 
the question of whether PSA screening 
reduces mortality [6,7].
However, emerging data has served only to 
emphasize concerns regarding the suitability 
of PSA as a screening test. While the poor 
sensitivity of PSA leads to many missed cases 
of clinically significant prostate cancer, the 
rate of over-diagnosis, or detection of 
clinically insignificant prostate cancer, is 
thought to be more than 50% [8–11]. In 
